Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00603473 |
Examine the efficacy, safety and pharmacokinetics of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures
Condition | Intervention | Phase |
---|---|---|
Epilepsies, Partial |
Drug: gabapentin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Patients With Partial Seizures When Other Antiepileptics Do Not Provide Satisfactory Effects |
Estimated Enrollment: | 95 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
gabapentin: Experimental |
Drug: gabapentin
Orally administered gabapentin
|
Ages Eligible for Study: | 3 Years to 15 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Pfizer CT.gov Call Center | 1-800-718-1021 |
Japan | |
Pfizer Investigational Site | Recruiting |
yamanashi, Japan | |
Pfizer Investigational Site | Recruiting |
Hiroshima, Japan | |
Pfizer Investigational Site | Recruiting |
Saitama, Japan | |
Pfizer Investigational Site | Not yet recruiting |
Yamagata, Japan | |
Japan, Hyogo | |
Pfizer Investigational Site | Recruiting |
Kobe, Hyogo, Japan | |
Japan, Ishikawa | |
Pfizer Investigational Site | Recruiting |
Kanazawa, Ishikawa, Japan | |
Japan, Kagawa | |
Pfizer Investigational Site | Not yet recruiting |
zentsuuji, Kagawa, Japan | |
Japan, Kanagawa Pref. | |
Pfizer Investigational Site | Recruiting |
Yokohama, Kanagawa Pref., Japan | |
Japan, Miyagi-ken | |
Pfizer Investigational Site | Recruiting |
Sendai-shi, Miyagi-ken, Japan | |
Japan, Nagoya | |
Pfizer Investigational Site | Recruiting |
Showa-Ku, Nagoya, Japan | |
Japan, Niigata | |
Pfizer Investigational Site | Recruiting |
Niigata-shi, Niigata, Japan | |
Japan, Okayama | |
Pfizer Investigational Site | Recruiting |
Okayama-shi, Okayama, Japan | |
Japan, Osaka | |
Pfizer Investigational Site | Recruiting |
Suita, Osaka, Japan | |
Pfizer Investigational Site | Recruiting |
Izumi-shi, Osaka, Japan | |
Japan, Shizuoka | |
Pfizer Investigational Site | Recruiting |
Shizuoka-shi, Shizuoka, Japan | |
Japan, Tokyo | |
Pfizer Investigational Site | Recruiting |
Shinjuku-ku, Tokyo, Japan | |
Pfizer Investigational Site | Recruiting |
Kodaira, Tokyo, Japan | |
Pfizer Investigational Site | Recruiting |
Kiyose-shi, Tokyo, Japan | |
Pfizer Investigational Site | Recruiting |
Setagaya-ku, Tokyo, Japan |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trials Disclosure Group ) |
Study ID Numbers: | A9451162 |
Study First Received: | January 16, 2008 |
Last Updated: | January 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00603473 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Epilepsies, Partial Excitatory Amino Acids Calcium, Dietary Gabapentin |
Epilepsy Seizures Central Nervous System Diseases Brain Diseases |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Nervous System Diseases Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Antiparkinson Agents Calcium Channel Blockers Excitatory Amino Acid Agents Cardiovascular Agents |
Antimanic Agents Pharmacologic Actions Membrane Transport Modulators Sensory System Agents Therapeutic Uses Anti-Anxiety Agents Analgesics Peripheral Nervous System Agents Central Nervous System Agents Anticonvulsants Excitatory Amino Acid Antagonists |